<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_1905-7415.1005.511_s_005_w2aab3b7b7b1b6b1aab1c16b1Aa"><h3>Background</h3><p>Major vascular invasion by hepatocellular carcinoma (HCC) is a poor prognostic factor. The outcome of hepatic resection for this advanced stage tumor remains unclear.</p></sec><sec id="j_1905-7415.1005.511_s_006_w2aab3b7b7b1b6b1aab1c16b2Aa"><h3>Objectives</h3><p>To clarify the outcome of hepatic resection for HCC with vascular invasion.</p></sec><sec id="j_1905-7415.1005.511_s_007_w2aab3b7b7b1b6b1aab1c16b3Aa"><h3>Methods</h3><p>Between January 2005 and May 2013, 13 of 272 patients who underwent hepatic resection of HCC had a confirmed major portal or hepatic vein tumor thrombosis. The perioperative and long-term outcomes of this cohort of patients were retrospectively reviewed.</p></sec><sec id="j_1905-7415.1005.511_s_008_w2aab3b7b7b1b6b1aab1c16b4Aa"><h3>Results</h3><p>Ten of the 13 patients underwent preoperative transarterial chemoembolization (TACE). None showed tumor progression or liver function deterioration. All underwent hepatic resection with complete removal of tumor thrombus. The vascular resection margin was microscopically negative in all patients. Postoperative complications occurred in 62%. Most complications were pleural effusion, which necessitates percutaneous drainage. No perioperative mortality occurred. The median follow up time was 38.5 months (range 10–112). The median overall survival was 38.5 months. The 1-, 3-, and 5-year recurrence free survival was 93%, 36%, and 36%, respectively. The 1-, 3-, and 5 year-overall survival was 93%, 76%, and 48%, respectively. Nine patients had intrahepatic tumor recurrence, extrahepatic recurrence, or both. Five with recurrence underwent TACE, radiofrequency ablation, or surgical resection. On univariate analysis, the only factor that tended to relate to worse overall survival was underlying liver cirrhosis (<italic>P</italic> = 0.056).</p></sec><sec id="j_1905-7415.1005.511_s_009_w2aab3b7b7b1b6b1aab1c16b5Aa"><h3>Conclusions</h3><p>Hepatic resection for HCC with invasive thrombosis, combined with careful patient selection, close postoperative follow up, and early treatment of recurrence offers a chance of long-term survival.</p></sec></abstract>

BackgroundMajor vascular invasion by hepatocellular carcinoma (HCC) is a poor prognostic factor. The outcome of hepatic resection for this advanced stage tumor remains unclear.ObjectivesTo clarify the outcome of hepatic resection for HCC with vascular invasion.MethodsBetween January 2005 and May 2013, 13 of 272 patients who underwent hepatic resection of HCC had a confirmed major portal or hepatic vein tumor thrombosis. The perioperative and long-term outcomes of this cohort of patients were retrospectively reviewed.ResultsTen of the 13 patients underwent preoperative transarterial chemoembolization (TACE). None showed tumor progression or liver function deterioration. All underwent hepatic resection with complete removal of tumor thrombus. The vascular resection margin was microscopically negative in all patients. Postoperative complications occurred in 62%. Most complications were pleural effusion, which necessitates percutaneous drainage. No perioperative mortality occurred. The median follow up time was 38.5 months (range 10–112). The median overall survival was 38.5 months. The 1-, 3-, and 5-year recurrence free survival was 93%, 36%, and 36%, respectively. The 1-, 3-, and 5 year-overall survival was 93%, 76%, and 48%, respectively. Nine patients had intrahepatic tumor recurrence, extrahepatic recurrence, or both. Five with recurrence underwent TACE, radiofrequency ablation, or surgical resection. On univariate analysis, the only factor that tended to relate to worse overall survival was underlying liver cirrhosis (P = 0.056).ConclusionsHepatic resection for HCC with invasive thrombosis, combined with careful patient selection, close postoperative follow up, and early treatment of recurrence offers a chance of long-term survival.


<div xmlns="http://www.w3.org/1999/xhtml"><p>Hepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer-related death worldwide [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_001_w2aab3b7b7b1b6b1ab1b9b1Aa">1</a>]. Evidence of invasion of a major vessel, such as a portal or hepatic vein tumor thrombus is poor prognostic factor for patient survival [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_002_w2aab3b7b7b1b6b1ab1b9b2Aa">2</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_003_w2aab3b7b7b1b6b1ab1b9b3Aa">3</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_004_w2aab3b7b7b1b6b1ab1b9b4Aa">4</a>]. Untreated patients with HCC who have portal vein tumor thrombus have short median survival, reported to be 2.7 months [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_005_w2aab3b7b7b1b6b1ab1b9b5Aa">5</a>].</p><p>The optimal treatment for this advanced staged HCC is controversial. The only treatment option that offers a chance of prolonged survival in selected patients is complete hepatic resection [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_006_w2aab3b7b7b1b6b1ab1b9b6Aa">6</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_007_w2aab3b7b7b1b6b1ab1b9b7Aa">7</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_008_w2aab3b7b7b1b6b1ab1b9b8Aa">8</a>].</p><p>The objective of this study was to clarify the outcomes of complete surgical resection for HCC with a major portal vein or hepatic vein tumor thrombus in selected patients with this advanced staged HCC.</p><sec id="j_1905-7415.1005.511_s_001_w2aab3b7b7b1b6b1ab1b3Aa"><div>Methods</div><p>The present retrospective cohort study was approved by the Institutional Review Board (IRB) of the Faculty of Medicine, Chulalongkorn University (certificate of approval No. 252/2015, IRB No. 608/ 57). After approval, we reviewed the medical records of patients who underwent liver resection for HCC between January 2005 and May 2013 at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Only data from patients who had a pathologically confirmed hepatocellular carcinoma-tumor thrombus in a major portal vein or hepatic vein were eligible for inclusion in the study.</p><p>Baseline history and physical examination were noted. Preoperative laboratory testing included complete blood count, blood urea nitrogen, serum creatinine, liver function test, prothrombin time, partial thromboplastin time, and liver imaging (triple phase computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen) and chest radiography. Patients with a hepatic vein tumor thrombus or with suspected lesions on chest radiographs had undergone CT of the chest. Liver function reserve was assessed using Child–Pugh scores, platelet counts, and evidence of significant portal hypertension. Residual liver volume was calculated by CT volumetry.</p><p>Preoperative transarterial chemoembolization (TACE) was performed using conventional lipiodol embolization in selected patients with borderline liver function preservation or as a bridging treatment before surgery.</p><p>All patients whose data were included had undergone hepatic resection. Anatomical hepatic resection had been performed according to the extent and location of tumor under limited liver mobilization. Pringle’s maneuver had been used intermittently during the parenchymal transection.</p><p>Tumor thrombi in a portal or hepatic vein had been removed according to the extent and location of the thrombi. If a tumor thrombus had been located within the resection line, it was removed together with the hepatic parenchymal transection. Where a tumor thrombus had extended beyond the hepatic parenchymal transection line, such as extension to the main portal vein or inferior vena cava, it had been removed from the opened stump of the vein. Vascular resection had not been necessary in any patient.</p><p>All patients had been followed up postoperatively with serum a-fetoprotein (AFP) measurements and CT or MRI of the abdomen every 2–3 months. Chest radiography or CT of the chest had been performed in selected patients.</p><p>Stata, version 13 (StataCorp, College Station, TX, USA) was used for all statistical analyses. Patient and tumor characteristics are described as mean (standard deviation, SD). Actuarial survival was calculated by using the Kaplan–Meier method. Univariate analysis to identify prognostic factors related to recurrence free and overall survival outcomes was conducted by using Cox proportional hazards models. <italic>P</italic> &lt; 0.05 was considered significant.</p></sec><sec id="j_1905-7415.1005.511_s_002_w2aab3b7b7b1b6b1ab1b4Aa"><div>Results</div><p>During the period examined, 13 (4.8%) of 272 patients who underwent hepatic resection for HCC had a pathologically confirmed tumor thrombus in a major portal vein or hepatic vein.</p><sec id="j_1905-7415.1005.511_s_002_s_001_w2aab3b7b7b1b6b1ab1b4b2Aa"><div>Patient and tumor characteristics</div><p>The baseline patients and tumor characteristics are shown in <bold><a ref-type="table" href="#j_1905-7415.1005.511_tab_001_w2aab3b7b7b1b6b1ab1b4b2b2aAa">Table 1</a></bold>. The majority of patients had hepatitis B-related liver disease and had a tumor thrombus in the first branch of a portal vein (right or left portal vein). All patients had Child–Pugh class A reserve function and high serum AFP levels. All patients had a pathologically proven tumor thrombus and 8 had pathologically proven liver cirrhosis.</p><p><table-wrap id="j_1905-7415.1005.511_tab_001_w2aab3b7b7b1b6b1ab1b4b2b2aAa" position="float"><label>Table 1</label><caption><p>Patient and tumor characteristics</p></caption><table rules="groups"><thead><tr><th>Characteristic</th><th>n (%) or mean (standard deviation)</th></tr></thead><tbody><tr><td>Age (years)</td><td align="center">51.4 (9.5)</td></tr><tr><td>Male sex</td><td align="center">12 (92)</td></tr><tr><td><bold>Underlying liver disease</bold></td><td align="center"></td></tr><tr><td> Hepatitis B virus (HBV)</td><td align="center">7 (54)</td></tr><tr><td> HBV and hepatitis C virus (HCV) HBV</td><td align="center">2 (15)</td></tr><tr><td>and hepatitis C infection (HCV)</td><td align="center">4 (31)</td></tr><tr><td> Non-HBV/HCV</td><td align="center"></td></tr><tr><td> Tumor diameter (cm)</td><td align="center">11.2 (5.9)</td></tr><tr><td> Child–Pugh A</td><td align="center">13 (100)</td></tr><tr><td> α-Fetoprotein at diagnosis (IU/mL)</td><td align="center">13615 (41129)</td></tr><tr><td><bold>Tumor thrombus location</bold></td><td></td></tr><tr><td> 2<sup>nd</sup> branch portal vein (PV)</td><td align="center">3 (23)</td></tr><tr><td> 1<sup>st</sup> branch PV (right or left PV)</td><td align="center">4 (31)</td></tr><tr><td> Main PV</td><td align="center">3 (23)</td></tr><tr><td> Hepatic vein/inferior vena cava</td><td align="center">3 (23)</td></tr></tbody></table></table-wrap></p><p>Ten patients (77%) underwent preoperative TACE. The median number of TACE sessions was 2 (range 1-4). None of these patients had tumor progression or liver function deterioration after TACE.</p></sec><sec id="j_1905-7415.1005.511_s_002_s_002_w2aab3b7b7b1b6b1ab1b4b3Aa"><div>Surgical outcomes and prognostic factors</div><p>Anatomical hepatic resections for HCC including tumor thrombectomy had been performed in 13 patients. Eleven (85%) underwent major hepatic resection (≥3 Couinaud segments). The perioperative outcomes are shown in <bold><a ref-type="table" href="#j_1905-7415.1005.511_tab_002_w2aab3b7b7b1b6b1ab1b4b3b2aAa">Table 2</a></bold>. Postoperative complications were occurred in 62%. The most common complication was pleural effusion, which necessitated percutaneous drainage. No perioperative death occurred. Ten patients had complete microscopic surgical resection (R0). Three patients had micro-scopically positive resection margins at hepatic parenchymal cut surface, but not at vascular resection margins.</p><p><table-wrap id="j_1905-7415.1005.511_tab_002_w2aab3b7b7b1b6b1ab1b4b3b2aAa" position="float"><label>Table 2</label><caption><p>Perioperative outcomes</p></caption><table rules="groups"><thead><tr><th></th><th>n (%) or mean (standard deviation)</th></tr></thead><tbody><tr><td><bold>Operative procedure</bold></td><td></td></tr><tr><td> Posterior sectionectomy</td><td align="center">2 (15)</td></tr><tr><td> Right/left hepatectomy</td><td align="center">10 (77)</td></tr><tr><td> Right trisectionectomy</td><td align="center">1 (8)</td></tr><tr><td>Operative time (min)</td><td align="center">323 (122.9)</td></tr><tr><td>Estimated blood loss (mL)</td><td align="center">1439 (1372.7)</td></tr><tr><td>Length of stay (days)</td><td align="center">14 (5.7)</td></tr><tr><td><bold>Complications</bold></td><td></td></tr><tr><td> Wound infection</td><td align="center">2</td></tr><tr><td> Pleural effusion</td><td align="center">5</td></tr><tr><td> Intraabdominal collection</td><td align="center">1</td></tr><tr><td> Bile leakage</td><td align="center">1</td></tr><tr><td><bold>Pathological results</bold></td><td></td></tr><tr><td>Resection margins</td><td></td></tr><tr><td> R0 (free margins)</td><td align="center">10 (77)</td></tr><tr><td> R1 (microscopically positive)</td><td align="center">3 (23)</td></tr><tr><td>Tumor differentiation</td><td></td></tr><tr><td> Moderate</td><td align="center">5 (39)</td></tr><tr><td> Poor</td><td align="center">8 (62)</td></tr><tr><td>Satellite nodule positive</td><td align="center">3 (23)</td></tr></tbody></table></table-wrap></p><p>All patients had complete postoperative follow up. The median follow up time was 38.5 months (range 10-112 months). The median overall survival was 38.5 months. The 1-, 3-, and 5 year-overall survival was 93%, 76% and 48%, respectively (<bold><a ref-type="fig" href="#j_1905-7415.1005.511_fig_001_w2aab3b7b7b1b6b1ab1b4b3b4aAa">Figure 1</a></bold>). The median recurrence free survival was 16 months. The 1-, 3-, and 5-year recurrence free survival was 93%, 36%, and 36%, respectively (<bold><a ref-type="fig" href="#j_1905-7415.1005.511_fig_002_w2aab3b7b7b1b6b1ab1b4b3b5aAa">Figure 2</a></bold>). Nine patients had tumor recurrence, 2 had intrahepatic recurrences, 4 had extrahepatic recurrences, and 3 had intra-and extrahepatic recurrences. For patients with isolated hepatic or extrahepatic recurrence, particularly lung metastases, we performed surgical resection.</p><p><figure id="j_1905-7415.1005.511_fig_001_w2aab3b7b7b1b6b1ab1b4b3b4aAa" position="float" fig-type="figure"><h2>Figure 1</h2><figCaption><p>Recurrence-free survival after hepatic resection with tumor thrombectomy</p></figCaption><img xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="graphic/j_1905-7415.1005.511_fig_001.jpg" src="https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470667783f1392090d68be5/j_1905-7415.1005.511_fig_001.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20240718T145435Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=18000&amp;X-Amz-Credential=AKIA6AP2G7AKP25APDM2%2F20240718%2Feu-central-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=2b1eabb49ac633fd71d338e2bcdbc1bed71626cf66eefd5b616d7864d5bb702f" class="mw-100"/></figure></p><p><figure id="j_1905-7415.1005.511_fig_002_w2aab3b7b7b1b6b1ab1b4b3b5aAa" position="float" fig-type="figure"><h2>Figure 2</h2><figCaption><p>Recurrence-free survival after hepatic resection with tumor thrombectomy</p></figCaption><img xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="graphic/j_1905-7415.1005.511_fig_002.jpg" src="https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470667783f1392090d68be5/j_1905-7415.1005.511_fig_002.jpg?X-Amz-Algorithm=AWS4-HMAC-SHA256&amp;X-Amz-Date=20240718T145435Z&amp;X-Amz-SignedHeaders=host&amp;X-Amz-Expires=17999&amp;X-Amz-Credential=AKIA6AP2G7AKP25APDM2%2F20240718%2Feu-central-1%2Fs3%2Faws4_request&amp;X-Amz-Signature=26a7c5ad32389fcd6fe9484cc6fb6c06e059e61704e89b4cd94e2f0009a7be83" class="mw-100"/></figure></p><p>Univariate Cox proportional hazards model analysis was conducted to determine prognostic factors related to recurrence free and overall survival (<bold><a ref-type="table" href="#j_1905-7415.1005.511_tab_003_w2aab3b7b7b1b6b1ab1b4b3b7aAa">Table 3</a></bold>). The only factor that tended to be related to worse overall survival was underlying liver cirrhosis. However, this relationship was not quite significant (<italic>P</italic> = 0.056).</p><p><table-wrap id="j_1905-7415.1005.511_tab_003_w2aab3b7b7b1b6b1ab1b4b3b7aAa" position="float"><label>Table 3</label><caption><p>Univariate Cox proportional hazards model analysis to identify prognostic factors related to recurrence free and overall survival</p></caption><table rules="groups"><thead><tr><th>Recurrence free survival <break></break>HR (95% CI), <italic>P</italic></th><th>Overall survival <break></break>HR (95% CI), <italic>P</italic></th><th>Prognostic factor</th></tr></thead><tbody><tr><td>0.81 (0.20 to 3.25), 0.76</td><td>0.70 (0.09 to 5.09), 0.72</td><td>Tumor size ≥10 cm</td></tr><tr><td>2.07 (0.41 to 10.45), 0.37</td><td>3.54 (0.50 to 25.28), 0.21</td><td>R0, tumor free resection margin</td></tr><tr><td>2.80 (0.56 to 14.02), 0.18</td><td><sup><fn id="j_1905-7415.1005.511_fn_001_w2aab3b7b7b1b6b1ab1b4b3b7ab2b1b2b1aaAa" symbol="a"><p><italic>P</italic>, no death of patients without cirrhosis during follow up</p></fn></sup>0.056</td><td>Liver cirrhosis</td></tr><tr><td>3.62 (0.44 to 30.04), 0.20</td><td><sup><fn id="j_1905-7415.1005.511_fn_002_w2aab3b7b7b1b6b1ab1b4b3b7ab2b1b3b1aaAa" symbol="b"><p><italic>P</italic>, no death of patients without preoperative transarterial chemoembolization during follow up</p></fn></sup>0.24</td><td>Preop transarterial chemoembolization</td></tr></tbody></table><table-wrap-foot><attrib>HR, hazard ratio; CI, confidence interval <italic>P</italic> &lt; 0.05 considered significant</attrib></table-wrap-foot></table-wrap></p></sec></sec><sec id="j_1905-7415.1005.511_s_003_w2aab3b7b7b1b6b1ab1b5Aa"><div>Discussion</div><p>Hepatocellular carcinoma with major vascular invasion is associated with a poor prognosis [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_002_w2aab3b7b7b1b6b1ab1b9b2Aa">2</a>]. Hepatic resection has remained the mainstay of treatment that offers a better chance of survival than alternative treatments [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_007_w2aab3b7b7b1b6b1ab1b9b7Aa">7</a>, <a ref-type="bibr" href="#j_1905-7415.1005.511_ref_008_w2aab3b7b7b1b6b1ab1b9b8Aa">8</a>]. The present study showed a favorable 5-year overall survival of 48%. Other studies have found a 5-year overall survival of 20%-31.3% [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_008_w2aab3b7b7b1b6b1ab1b9b8Aa">8</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_009_w2aab3b7b7b1b6b1ab1b9b9Aa">9</a>,<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_010_w2aab3b7b7b1b6b1ab1b9c10Aa">10</a>]. However, in general, the survival outcomes of hepatic resection for this advanced staged HCC are improving. Other treatment options for this group of patients, such as TACE alone or sorafenib had worse survival outcomes than hepatic resection [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_008_w2aab3b7b7b1b6b1ab1b9b8Aa">8</a>, <a ref-type="bibr" href="#j_1905-7415.1005.511_ref_011_w2aab3b7b7b1b6b1ab1b9c11Aa">11</a>, <a ref-type="bibr" href="#j_1905-7415.1005.511_ref_012_w2aab3b7b7b1b6b1ab1b9c12Aa">12</a>].</p><p>Preoperative TACE was not associated with better overall survival in resectable hepatocellular carcinoma [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_013_w2aab3b7b7b1b6b1ab1b9c13Aa">13</a>, <a ref-type="bibr" href="#j_1905-7415.1005.511_ref_014_w2aab3b7b7b1b6b1ab1b9c14Aa">14</a>]. However, preoperative TACE was a safe and efficacious procedure with high rates of pathological response [<a ref-type="bibr" href="#j_1905-7415.1005.511_ref_013_w2aab3b7b7b1b6b1ab1b9c13Aa">13</a>]. The role of preoperative TACE for treatment of hepatocellular carcinoma with tumor thrombus remains controversial. In the present study, 10 patients had received preoperative TACE, and none of them had tumor progression. However, the present study did not show any benefits of preoperative TACE in terms of improved prognosis for survival outcomes. A possible benefit of preoperative TACE was the better selection of patients with questionable liver function reserve for surgery. Liver function markedly deteriorates after TACE in patients with borderline liver function reserve. These patients may not be good candidate for hepatic resection. No patients in the present study had deteriorated liver function after TACE, and so had undergone hepatic resection as planned without postoperative liver failure.</p><p>Patients whose data were included in the present study only underwent tumor thrombectomy, and the resection of vessels was not attempted, except where the vessel wall was obviously invaded by the tumor. In the present study, 3 patients had a microscopically positive resection margin at the hepatic parenchymal cut surface, but not a major vascular resection margin. Two patients underwent postoperative radiation therapy. Survival outcomes of patients with a free resection margin (R0) were not significantly different to those in patients with a positive resection margin (R1). However, the reliability of this outcome is limited by the availability of data from only a small number of patients.</p><p>Postoperative surveillance is important for the early detection of either intrahepatic or extrahepatic tumor recurrence. Liver CT or MRI and serum AFP tests were performed every 2–3 months especially during the first 2 postoperative years. Seven of 9 patients with tumor recurrence underwent various treatments according to site and number of tumor recurrences, liver function reservation, and performance status of patients. Treatment options included surgical resection, ablation, TACE, and systemic treatment. We recommend considering early aggressive treatment of tumor recurrence in all patients.</p><p>The main limitations of this study were the availability of data from only a small number of patients and possible some selection bias of patients with favorable risk and well-preserved liver function. Nevertheless, in the selected patients, the present study shows favorable long-term survival outcomes for complete surgical resection of hepatocellular carcinoma with tumor thrombus.</p></sec><sec id="j_1905-7415.1005.511_s_004_w2aab3b7b7b1b6b1ab1b6Aa"><div>Conclusion</div><p>Hepatic resection and complete tumor thrombectomy in patients with advanced-stage hepatocellular carcinoma, combined with careful preoperative patient selection, close postoperative follow up, and early treatment of the recurrent tumor may offer a chance of long-term survival for some patients.</p></sec></div>

Outcomes of hepatic resection for hepatocellular carcinoma with major portal or hepatic vein tumor thrombosis: retrospective cohort study

Department of Surgery, Faculty of Medicine, King Chulalongkorn Memorial Hospital

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundMajor vascular invasion by hepatocellular carcinoma (HCC) is a poor prognostic factor. The outcome of hepatic resection for this advanced stage tumor...

Outcomes of hepatic resection for hepatocellular carcinoma with major portal or hepatic vein tumor thrombosis: retrospective cohort study

Article Category: Brief communication (Original)

Publicado en línea: 31 mar 2017

Páginas: 477 - 482

DOI: https://doi.org/10.5372/1905-7415.1005.511

Palabras clave
Hepatocellular carcinoma, preoperative TACE, surgical resection, survival outcomes, tumor thrombus

© 2016 Wipusit Taesombat, Boonchoo Sirichindakul, Bunthoon Nonthasoot, Jade Suphapol, Methee Sutherasan, Supanit Nivatvongs

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Outcomes of hepatic resection for hepatocellular carcinoma with major portal or hepatic vein tumor thrombosis: retrospective cohort study

Article Category: Brief communication (Original)

Publicado en línea: 31 mar 2017

Páginas: 477 - 482

DOI: https://doi.org/10.5372/1905-7415.1005.511

Palabras claveHepatocellular carcinoma, preoperative TACE, surgical resection, survival outcomes, tumor thrombus

© 2016 Wipusit Taesombat, Boonchoo Sirichindakul, Bunthoon Nonthasoot, Jade Suphapol, Methee Sutherasan, Supanit Nivatvongs

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Palabras clave
Hepatocellular carcinoma, preoperative TACE, surgical resection, survival outcomes, tumor thrombus